DK478788D0 - Polymorf modifikation af forbindelsen 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro-(4.5) decan-7,9-dion - Google Patents

Polymorf modifikation af forbindelsen 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro-(4.5) decan-7,9-dion

Info

Publication number
DK478788D0
DK478788D0 DK478788A DK478788A DK478788D0 DK 478788 D0 DK478788 D0 DK 478788D0 DK 478788 A DK478788 A DK 478788A DK 478788 A DK478788 A DK 478788A DK 478788 D0 DK478788 D0 DK 478788D0
Authority
DK
Denmark
Prior art keywords
polymorf
dion
decan
azaspiro
piperazinyl
Prior art date
Application number
DK478788A
Other languages
English (en)
Other versions
DK478788A (da
DK170821B1 (da
Inventor
Jack C Simms
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22225222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK478788(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DK478788D0 publication Critical patent/DK478788D0/da
Publication of DK478788A publication Critical patent/DK478788A/da
Application granted granted Critical
Publication of DK170821B1 publication Critical patent/DK170821B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Body Structure For Vehicles (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DK478788A 1987-08-28 1988-08-26 Lavere smeltende polymorf, krystallinsk form af buspiron, hydrochlorid, samt farmaceutisk præparat indeholdende denne polymorfe form DK170821B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/090,984 US5015646A (en) 1987-08-28 1987-08-28 Pharmaceutically useful polymorphic modification of buspirone
US9098487 1987-08-28

Publications (3)

Publication Number Publication Date
DK478788D0 true DK478788D0 (da) 1988-08-26
DK478788A DK478788A (da) 1989-03-01
DK170821B1 DK170821B1 (da) 1996-01-29

Family

ID=22225222

Family Applications (1)

Application Number Title Priority Date Filing Date
DK478788A DK170821B1 (da) 1987-08-28 1988-08-26 Lavere smeltende polymorf, krystallinsk form af buspiron, hydrochlorid, samt farmaceutisk præparat indeholdende denne polymorfe form

Country Status (22)

Country Link
US (1) US5015646A (da)
EP (1) EP0304941B1 (da)
JP (1) JP2716740B2 (da)
KR (1) KR970011297B1 (da)
AT (1) ATE101147T1 (da)
AU (1) AU618549B2 (da)
CY (1) CY1785A (da)
DE (1) DE3887598T2 (da)
DK (1) DK170821B1 (da)
ES (1) ES2061576T3 (da)
FI (1) FI883961A (da)
HK (1) HK74494A (da)
HU (1) HU201322B (da)
IE (1) IE63071B1 (da)
IL (1) IL87468A (da)
MY (1) MY104061A (da)
NO (1) NO883805D0 (da)
NZ (1) NZ225896A (da)
OA (1) OA08908A (da)
PT (1) PT88356B (da)
YU (1) YU46962B (da)
ZA (1) ZA886082B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
DE69941672D1 (de) 1998-06-19 2010-01-07 Teijin Ltd Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung
US6465255B1 (en) * 1999-01-29 2002-10-15 The Regents Of The University Of California Method for identifying and probing phase transitions in materials
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4351939A (en) * 1980-10-16 1982-09-28 Mead Johnson & Company Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen

Also Published As

Publication number Publication date
KR890003740A (ko) 1989-04-17
CY1785A (en) 1995-10-20
IE63071B1 (en) 1995-03-22
PT88356B (pt) 1995-03-31
EP0304941A1 (en) 1989-03-01
OA08908A (en) 1989-10-31
DE3887598D1 (de) 1994-03-17
FI883961A (fi) 1989-03-01
HK74494A (en) 1994-08-05
KR970011297B1 (ko) 1997-07-09
DE3887598T2 (de) 1994-05-19
DK478788A (da) 1989-03-01
ES2061576T3 (es) 1994-12-16
AU618549B2 (en) 1992-01-02
NZ225896A (en) 1991-04-26
YU46962B (sh) 1994-09-09
EP0304941B1 (en) 1994-02-02
JP2716740B2 (ja) 1998-02-18
HU201322B (en) 1990-10-28
FI883961A0 (fi) 1988-08-26
ATE101147T1 (de) 1994-02-15
JPS6471816A (en) 1989-03-16
PT88356A (pt) 1989-06-30
HUT47564A (en) 1989-03-28
IL87468A0 (en) 1989-01-31
DK170821B1 (da) 1996-01-29
IL87468A (en) 1992-12-01
AU2107688A (en) 1989-03-02
IE882528L (en) 1989-02-28
YU161688A (en) 1990-10-31
US5015646A (en) 1991-05-14
MY104061A (en) 1993-11-30
ZA886082B (en) 1989-04-26
NO883805D0 (no) 1988-08-25

Similar Documents

Publication Publication Date Title
DK478788D0 (da) Polymorf modifikation af forbindelsen 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro-(4.5) decan-7,9-dion
DE69327567T2 (de) Verfahren zur Herstellung von Alanylglutamin
DE69101802D1 (de) Antihypercholesterolemika.
KR960009263B1 (en) Process of producing sulfonylurea derivatives
NO874872D0 (no) Kondenderte heterocykliske tetrahydroaminokinolinoler og beslektede forbindelser samt fremgangsmaate for fremstilling derav.
ES2053707T3 (es) Procedimiento para la preparacion de amidas de acidos 3,3-diaril-acrilicos.
GR3023381T3 (en) Process for preparing trans-piperidine-2,5-dicarboxylates
DK0821955T3 (da) Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
DE69002340D1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung.
ES552874A0 (es) Un procedimiento para preparar benzo (c)-1,5-naftiridinas
DE3750023D1 (de) Verfahren zur Herstellung von 2-(1-Pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)Thiazol und dessen kristallinisches Dihydrochlorid-Trihydrat.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
FI923914A0 (fi) Foerfarande foer framstaellning av 2-(substituerad fenyl)-1,2,4-triazin-3,5(2h,4h)-dionderivat.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK